A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From a Prograf Based Immunosuppressive Regimen to a Tacrolimus Prolonged Release, Advagraf Based Immunosuppressive Regimen, Including a Long-Term Follow-Up

Trial Profile

A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From a Prograf Based Immunosuppressive Regimen to a Tacrolimus Prolonged Release, Advagraf Based Immunosuppressive Regimen, Including a Long-Term Follow-Up

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2017

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Allotransplant rejection
  • Focus Pharmacokinetics
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 30 Jun 2017 Planned End Date changed from 1 Jun 2026 to 1 May 2026.
    • 01 Feb 2017 This trial has been completed in France (end date: 2016-10-28) as per European Clinical Trials Database.
    • 30 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2026.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top